米拉贝隆与奥昔布宁对既往使用抗毒蕈碱药物治疗的膀胱过度活动症患者的相对疗效及安全性：一项网状Meta分析
The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.
作者信息
Lozano-Ortega Greta, Walker David, Rogula Basia, Deighton Alison, Johnston Karissa, Hawkins Neil, Dmochowski Roger
机构信息
Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada.
Astellas Pharma Global Development, Inc., Northbrook, IL.
出版信息
Urology. 2019 May;127:1-8. doi: 10.1016/j.urology.2019.02.005. Epub 2019 Feb 18.
OBJECTIVE
To compare the efficacy and safety of mirabegron and onabotulinumtoxinA in the management of treatment-experienced patients with overactive bladder.
METHODS
The network meta-analysis was based on evidence from a systematic literature review of randomized controlled trials and a post-hoc analysis of treatment-experienced subpopulations from mirabegron studies.
RESULTS
Nineteen trials described in 21 publications were included.
CONCLUSION
Overall, compared to mirabegron, there was some evidence that onabotulinumtoxinA was associated with improved outcomes, including reductions in the number of micturitions in a 24-hour period, and the number of incontinence episodes. However, mirabegron was associated with a lower risk of urinary tract infections compared with onabotulinumtoxinA.
目的
比较米拉贝隆和A型肉毒毒素在治疗膀胱过度活动症的经验丰富患者中的疗效和安全性。
方法
网络荟萃分析基于对随机对照试验的系统文献综述证据以及米拉贝隆研究中治疗经验丰富亚组的事后分析。
结果
纳入了21篇出版物中描述的19项试验。
结论
总体而言，与米拉贝隆相比，有一些证据表明A型肉毒毒素与改善结局相关，包括24小时内排尿次数减少以及尿失禁发作次数减少。然而，与A型肉毒毒素相比，米拉贝隆发生尿路感染的风险较低。
Zotero 插件